The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | Obinutuzumab/chlorambucil gives OS benefit over rituximab in frontline CLL
Exciting updates on obinutuzumab were presented at the 23rd congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. Final analysis results from the CLL11 study (NCT01010061) were presented at the press briefing by Dr Valentin Goede, of the German CLL Study Group, Cologne, Germany. Dr Goede highlights the overall survival benefit of obinutuzumab plus chlorambucil over rituximab in patients with chronic lymphocytic leukemia (CLL) and comorbidities.
